A Randomized, Double-Blind, Placebo-Controlled, Two Part Trial (Sequential Single Subcutaneous Dose Rising Trial and Semi-Sequential Multiple Subcutaneous Dose Response Trial) to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0453 in Overweight/Obese Male and Female Subjects.
Phase of Trial: Phase I/II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs NN 9161 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 30 Nov 2011 Planned end date changed from 1 Sep 2015 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 30 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Feb 2011 Planned end date changed from 1 Nov 2010 to 1 Sep 2015 as reported by ClinicalTrials.gov.